isoniazid and Fibrosis

isoniazid has been researched along with Fibrosis in 10 studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

Research

Studies (10)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse Events and the Severity of Any Adverse Events.

"The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.~The following parameters will be assessed for both groups:~Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of unsolicited adverse events for 28 days following the vaccination~Change from baseline for safety laboratory measures~Occurrence of serious adverse events during the whole study duration" (NCT02485912)
Timeframe: 26 weeks

To Assess the Immunogenicity Generated by Heterologous Prime-boost Immunisation With Monovalent ChAd3-EBO Z (2.5 x 1010 vp - 3.7 x 1010vp) and MVA-EBO Z (1.0 x 108 Pfu) in Healthy Senegalese Volunteers Aged 18-50 Years

"Ebolavirus specific immunogenicity will be assessed by a variety of immunological assays. The primary immunogenicity outcome measures are ELISA and neutralization antigen-specific assays for antibody responses and intracellular cytokine staining (ICS) assay for T cell responses.~Exploratory outcome measures will include ex-vivo ELISPOT, plasma blast assays and flow cytometry performed with research samples collected at different study timepoints as well as other immunogenicity assays throughout the study. An evaluation of genetic factors associated with immune responses may be performed as exploratory evaluation. Vaccine-induced mRNA expression profiles during 1 week after vaccination may also be performed as an exploratory evaluation." (NCT02485912)
Timeframe: 26 weeks

Reviews

2 reviews available for isoniazid and Fibrosis

Other Studies

8 other studies available for isoniazid and Fibrosis